ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
NICE reject two treatments for fatal, ultra-rare disease – hATTR
pharmafile
December 14, 2018The NHS’ cost effectiveness body NICE has rejected two treatments for the rare inherited condition, hereditary transthyretin-related amyliodsis (hATTR), over concerns as to whether the drugs showed long term benefits. -
FDA delays decision on inotersen, handing lead to Alnylam
fiercebiotech
May 07, 2018The FDA has delayed the PDUFA date for Akcea’s hereditary TTR amyloidosis drug inotersen, handing first-mover advantage to Alnylam. Akcea suffered the setback after the FDA asked for more time to review its response to requests for information ...
Pharma Sources Insight January 2025
